Navigation Links
Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid

new SEROQUEL® sustained release formulation studies presented at the congress show that patients who are currently receiving original formulation quetiapine, or who are inadequately treated with another antipsychotic agent, could be easily switched to SEROQUEL® sustained release formulation. Among clinically stable patients who switched from original formulation quetiapine, there were no significant differences between SEROQUEL sustained release formulation and the original formulation quetiapine in PANSS total scores after six weeks’ treatment (mean PANSS total score at day 42 was 55.4 and 54.8 for the sustained release formulation and the original formulation respectively) and the incidence of adverse events was similar (Study 146). Among patients who switched to SEROQUEL® sustained release formulation from other antipsychotics, 62.8 percent achieved improved clinical benefit (based on CGI-CB scores) regardless of the reason for switching (insufficient efficacy or intolerability of initial treatment, Study 147).

Based on these data and data from other trials, regulatory filings for the treatment of schizophrenia with SEROQUEL® sustained release formulation were submitted to the authorities in the US, EU and other markets in 2006. Beyond schizophrenia, ongoing clinical studies of SEROQUEL® sustained release formulation cover bipolar disorder, major depressive disorder and generalised anxiety disorder. SEROQUEL® (original formulation quetiapine) is the number one prescribed atypical antipsychotic in the United States and global sales for SEROQUEL® reached $3.4 billion in 2006. It is licensed in 85 countries for the treatment of schizophrenia, in 73 countries for the treatment of mania associated with bipolar disorder, and in October 2006 it was approved in the US by the FDA for the treatment of bipolar depression. It is estimated that more than 19 million patients have used SEROQUEL® worldwide since its launch in 1997.'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
7. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
10. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Medical Science ... As the key link between the medical device industry ... even more in the coming years as the device ... According to research by benchmarking firm, Best ... can gain an important edge is by harnessing new ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a global leader ... today announced it will participate in the 33 rd ... in San Francisco . ... speak at 11:00 AM Pacific Time.  A live audio webcast ... Investor Relations link on the Cyberonics home page at ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... BioStorage Technologies, Inc., a worldwide provider of long- ... chain logistics, will expand its European operations with the ... meters) full-service biorepository in Frankfurt, Germany. , BioStorage Technologies, ... growth plan to accommodate a rapidly growing list of ...
... PRINCETON, N.J., Oct. 21 PharmaNet Development Group, Inc., ... biotechnology, generic drug and medical device companies, today announced ... Trials Conference taking place at the World Trade Center ... , At the conference, top management will discuss ...
Cached Medicine Technology:BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility 2PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam 2
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
(Date:12/25/2014)... December 25, 2014 Parker & Sons, ... customer service and affordable quality regarding heating, cooling and ... recognition in 2014 by the “Queen of Clean” for ... earned an impressive reputation over the years for providing ... wide range of contractor services for both homeowners and ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected ... 30 years of practice experience in Dallas, Texas, has ... of dietary detoxification. The second study is scheduled to ... from test patients who just completed a 21-day detoxification ... in conducting the study, Dr. Casad said, "About 10 ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Dr. ... announced the expansion of his practice and med-spa with ... the practice’s growing list of cosmetic treatments and services. ... solution into the skin,” says Dr. Ho. “As a ... changes such as wrinkles, sun spots, discolorations or blemishes.” ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... treatment in adults as well as children , , MONDAY, ... off-label use of anticancer drugs in adults and children ... of that off-label use was for palliative care, say ... countries. , In off-label use, a drug is used ...
... DALLAS, Oct. 27 From Illinois to California, ... (Connecting About,Real Experiences) to find out about patients, ... visit. Hospitals participating in the initial,launch of this ... IL;,Clovis Community Medical Center in Clovis, CA; HealthONE ...
... 27 Accuray,Incorporated (Nasdaq: ARAY ), a global ... management is scheduled to present at the 19th,Annual Oppenheimer ... at 10:00 a.m. EST (7:00 a.m. PST.), A ... from the,investor relations page of the Company,s Web site ...
... New, dual action iron supplement pill with virtually no ... and nutritional benefits from ... iron to be available without prescription, CHICAGO, Oct. ... (http://www.alavenpharm.com ), an over-the-counter,iron supplement that offers both ...
... 5-Aminosalicylates Will Continue to be Used in ... Report from Decision Resources, WALTHAM, Mass., ... the,world,s leading research and advisory firms focusing ... Tanabe,s,Remicade is currently the leading biologic for ...
... to be presented Saturday, November 1, 2008 at this ... Francisco, California, October 31-November 4, SAN FRANCISCO, Oct. ... for a liver transplantation and 22,863 adults,who received transplantation ... that the increase in posttransplant,mortality caused by differences in ...
Cached Medicine News:Health News:Most Off-Label Cancer Drug Use for Palliative Care 2Health News:The Beryl Companies Launches CARE Calls Program in Five Hospitals Across U.S. 2Health News:Accuray Incorporated to Speak at Oppenheimer Healthcare Conference 2Health News:First-Ever Over-the-Counter Dual Action Iron Supplement Launched at the American Dietetic Association Conference in Chicago; Bifera to be Available in Select Stores in Early 2009 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
... (10 to 12) brain slices to be ... maintaining excellent viability. A mixture of 95% ... This initiates a circular flow and oxygen ... Slices remain viable for hours while awaiting ...
... provides a convenient reservoir of cooling water for the ... extended period of time or in a location which ... the hot side of the thermoelectric heat pump. ... is adequate to run the 900R for up to ...
Punch set for Advanced Tissue Arrayer, 0.6 mm...
Medicine Products: